Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT00924703

Condition

Phenylketonuria

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.

Eligibility Criteria

Birth Sex

All

Age

16 Years to 55 Years

Healthy Volunteers

No

Drug/Treatment:

rAvPAL-PEG

Phase:

Phase 2

Study Type:

Interventional

Number of Participants:

68

Study Started:

2010-01-13

Study Updated:

2021-10-12

Trial Locations

  • The Children's Hospital

    Aurora, Colorado, United States

  • University of Florida

    Gainesville, Florida, United States

  • Ann and Robert H Lurie Children's Hospital

    Chicago, Illinois, United States

  • University of Louisville, Kosair Charities Pediatric Clinical Research Unit

    Louisville, Kentucky, United States

  • Children's Hospital Boston

    Boston, Massachusetts, United States

  • University of Missouri

    Columbia, Missouri, United States

  • Washington University Center for Applied Research Sciences

    Saint Louis, Missouri, United States

  • Nebraska Medical Center

    Omaha, Nebraska, United States

  • Albany Medical Center

    Albany, New York, United States

  • Mount Sinai School of Medicine

    New York, New York, United States

  • Oregon Health and Science University

    Portland, Oregon, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, United States

  • University of Utah Hospital

    Salt Lake City, Utah, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, United States

Inclusion Criteria

  • Must have completed participation in previous rAvPAL-PEG studies.
  • Willing and able to provide written, signed informed consent, or, in the case of participants under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures.
  • Willing and able to comply with all study procedures.
  • Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
  • Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
  • Maintained a stable diet.
  • In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and electrocardiogram (ECG) at Screening.

Exclusion Criteria

  • Use of any investigational product (with the exception of rAvPAL-PEG) or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Use of any medication that is intended to treat PKU within 14 days prior to the administration of study drug.
  • Use or planned use of any injectable drugs containing PEG (other than rAvPAL-PEG), including Depo-Provera during study participation.
  • A prior reaction that included systemic symptoms (eg, generalized hives, respiratory or gastrointestinal problems, hypotension, angioedema, anaphylaxis) to rAvPAL-PEG or a PEG-containing product.
  • Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
  • Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study.
  • Known hypersensitivity to rAvPAL-PEG or its excipients, including hypersensitivity reactions that necessitated early termination from previous rAvPAL-PEG studies.
  • Alanine aminotransferase (ALT) concentration > 2 times the upper limit of normal.
  • Creatinine > 1.5 times the upper limit of normal

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our clinical trials.

By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.

*required fields

"*" indicates required fields

This field is hidden when viewing the form
This field is hidden when viewing the form